4-Aminopyrimidine tetrahydronaphthols: A series of novel vanilloid receptor-1 antagonists with improved solubility properties

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 6, 2008, Pages 1830-1834

  Doherty, Elizabeth M ^a   Retz, Daniel ^a   Gavva, Narender R ^a   Tamir, Rami ^a   Treanor, James J S ^a   Norman, Mark H ^a  

^a AMGEN INC   (United States)

Author keywords

TRPV1; VR1

Indexed keywords

4 AMINOPYRIMIDINE TETRAHYDRONAPHTHOL DERIVATIVE; 8 [6 [4 (TRIFLUOROMETHYL)PHENYL]PYRIMIDIN 4 YLAMINO] 1,2,3,4 TETRAHYDRONAPHTHALEN 2 OL; AMG 517; NAPHTHOL DERIVATIVE; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 1 BLOCKING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; HUMAN; IC 50; LIVER CELL; NONHUMAN; RAT; RECEPTOR BLOCKING; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZOTHIAZOLES; BLOOD FLOW VELOCITY; CALCIUM; CAPSAICIN; CHO CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRICETINAE; CRICETULUS; HEPATOCYTES; HUMANS; METABOLIC CLEARANCE RATE; MOLECULAR STRUCTURE; NAPHTHOLS; PYRIMIDINES; RATS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TRPV CATION CHANNELS;

RATTUS;

EID: 40749143959     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.02.022     Document Type: Article

References (22)

1. Szallasi A., and Blumberg P.M. Pharmacol. Rev. 51 (1999) 159
2. Caterina M.J., Leffler A., Malmberg A.B., Martin W.J., Trafton J., Petersen-Zeitz K.R., Koltzenburg M., Basbaum A.I., and Julius D. Science 288 (2000) 306
3. Davis J.B., Gray J., Gunthrope M.J., Hatcher J.P., Davey P.T., Overend P., Harries M.H., Latcham J., Clapham C., Atkinson K., Hughes S.A., Rance K., Grau E., Harper A.J., Pugh P.L., Rogers D.C., Bingham S., Randall A., and Sheardown S.A. Nature 405 (2000) 183
4. Immke D.C., and Gavva N.R. Semin. Cell Dev. Biol. 17 (2006) 582
5. Szallasi A., Cortright D.N., Blum C.A., and Eid S.R. Nat. Rev. Drug Discov. 6 (2007) 357
6. Westaway S.M. J. Med. Chem. 50 (2007) 2589
7. Rami H.K., and Gunthorpe M.J. Drug Discov. Today: Ther. Strategies 1 (2004) 97
8. Chakrabarti P.P., Chen N., Doherty E.M., Dominguez C., Falsey J.R., Fotsh C.H., Hulme C., Katon J., Nixey T., Norman M.H., Ognyanov V.I., Pettus L.H., Rzasa R.M., Stec M., Wang H.-L., and Zhu J. WO 04014871 (2004)
9. Doherty E.M., Bannon A.W., Bo Y., Chen N., Dominguez C., Falsey J., Fotsch C., Gavva N.R., Katon J., Nixey T., Ognyanov V.I., Pettus L., Rzasa R., Stec M., Surapaneni S., Tamir R., Zhu J., Treanor J.J.S., and Norman M.H. J. Med. Chem. 50 (2007) 3515
10. Wang H.-L., Katon J., Balan C., Bannon A.W., Bernard C., Doherty E.M., Dominguez C., Gavva N.R., Gore V., Ma V., Nishimura N., Surapaneni S., Tang P., Tamir R., Thiel O., Treanor J.J.S., and Norman M.H. J. Med. Chem. 50 (2007) 3528
11. Wang X., Chakrabarti P.P., Ognyanov V.I., Pettus L.H., Tamire R., Tan H., Tang P., Treanor J.J.S., Gavva N.R., and Norman M.H. Bioorg. Med. Chem. Lett. 17 (2007) 6539
12. Subsequent to our identification of naphthol ureas from HTS, examples of naphthol and tetrahydronaphthol ureas as TRPV1 antagonists appeared in the patent literature:. Yura T., Mogi M., Ikegami Y., Masuda T., Kokubo T., Urbahns K., Lowinger T.B., Yoshida N., Freitag J., Meier H., Wittka-Nopper R., Marumo M., Shiroo M., Tajimi M., Takeshita K., Moriwaki T., and Tsukimi Y. WO 014064 (2003)
13. Tajimi M., Kokubo T., Shiroo M., Tsukimi Y., Yura T., Urbahns K., Yamamoto N., Mogi M., Fujishima H., Masuda T., Yoshida N., and Moriwaki T. WO 052846 (2004)
14. For detailed assay conditions see. Doherty E.M., Fotsch C., Bo Y., Chakrabarti P.P., Chen N., Gavva N., Han N., Kelly M.G., Kincaid J., Klionsky L., Liu Q., Ognyanov V.I., Tamir R., Wang X., Zhu J., Norman M.H., and Treanor J.J.S. J. Med. Chem. 48 (2005) 71
15. Compound 3 was prepared as described in Ref. 4a.
16. For comparison, the reported pKa values for 4-methoxypyrimidine and 4-aminomethylpyrimidine are 2.5 and 6.1, respectively. Brown D.J., and Short L.N. J. Chem. Soc. (1953) 331
17. Tan H., Semin D., Wacker M., and Cheetham J. JALA 10 (2005) 364
18. TM AD column; mobile phase 25% EtOH in hexane; flow rate 30 mL/min; (+)-4 was the first to elute. The isolated antipodes were >99% enantiomeric purity as determined by chiral analytical LC.
19. In vitro metabolism was examined by incubating compound 4 at a concentration of 10 μM with rat hepatocytes (1 million cells/mL) for 4 h at 37 °C. Control incubations in the absence of cells were also carried out. Reactions were quenched with acetonitrile containing 0.05% formic acid. The supernatant was analyzed by reverse phase (YMC ODS-AQ, 4.6 × 250 mm, 5 μm) HPLC-MS/MS with radiometric detection and ion trap mass spectrometry using electrospray ionization. Hydrolysis experiments were conducted with glucoronidase and/or sulfatase to confirm the presence of glucoronide and/or sulfate metabolites.
20. Stjernlof P., Ennis M.D., Hansson L.O., Hoffman R.L., Ghazal N.B., Sundell S., Smith M.W., Svensson K., Carlsson A., and Wikstrom H. J. Med. Chem. 38 (1995) 2202
21. Yin J., and Buchwald S.L. Org. Lett. 2 (2000) 1101
22. Kawamura K., Ohta T., and Otani G. Chem. Pharm. Bull. 38 (1990) 2088